As new options for the treatment of disease become available, a protocol arises that is based on the FDA indications and national guidelines. In the case of atherosclerotic cardiovascular disease, patients are being denied coverage for the majority of prescriptions written for PCSK9 inhibitors despite meeting the indications. 

Learning Objectives

  • Review clinical definitions and identification of the clinically relevant patients for therapy.
  • Examine barriers to care including cost, insurance coverage, and clinician and patient reluctance.
  • Produce a consensus document based off of panel discussions and agreements that can be published and used to guide future discussions at the local and national levels. 

Faculty Disclosures

Seth Baum, MD,FASPC

President, American Society for Preventive Cardiology 

Paul Jellinger, MD, MACE

Past President American Association of Clinical Endocrinologists 


Secretary, American Society for Preventive 

James A. Underberg, MD, MS, FACPM, FACP, FNLA

Board of Directors, American Society for Preventive Cardiology 

Pamela Morris, MD,FACC, FASPC

Prevention of CVD Section Chair, American College of Cardiology

Joyce Ross, MSN, CRNP, FNLA

President, National Lipid Association

Katherine Wilemon, MD, FACC

Founder/CEO, The FH Foundation 

Commercial Supporter

Sponsored by ASPC with support from Amgen and Sanofi Regeneron  

Unraveling a Therapeutic Conundrum: A Town Hall on Barriers to Access PCSK9 Inhibitors

comments powered by Disqus